Physician profile
Himanshu Doshi
NPI 1508865551
$740.73
in general payments reported to CMS, 2019-2025
18 companies · $206 in 2025
The $206 reported for 2025 was more than what 80% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $45.60 · 2022: $103 · 2023: $52.49 · 2024: $138 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $113.32 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $94.61 | 2022-2025 | |
| Astellas Pharma US INC | $87.42 | 2019-2025 | Xtandi, Vyloy |
| Foundation Medicine, INC. | $63.50 | 2019 | |
| Emd Serono, INC. | $43.27 | 2022-2024 | |
| Seagen INC. | $41.33 | 2019-2023 | Padcev |
| Regeneron Healthcare Solutions, INC. | $38.10 | 2025 | Lynozyfic |
| Exelixis INC. | $37.15 | 2019-2022 | |
| Biomerieux INC | $36.13 | 2019 | |
| Merck Sharp & Dohme LLC | $34.39 | 2020-2024 | Keytruda |
| Daiichi Sankyo INC. | $28.91 | 2025 | Enhertu |
| Lilly USA, LLC | $25.67 | 2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $20.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2020 | |
| Tesaro, INC. | $15.42 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $14.72 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $13.95 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.51 | 2024 | Alunbrig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himanshu Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.